Rationale: Insulin-like peptide 5 (INSL5) is a hormone produced by enteroendocrine L-cells in the colon that has recently been implicated in the control of metabolic homeostasis.
the stimulation of food-intake. 3 Consistent with an orexigenic function, Grosse et al 3 reported a fall in INSL5 plasma levels after refeeding of starved mice; however, they observed poor reproducibility and batch dependence of several commercially available immunoassays. The detected plasma concentrations varied widely, 3 but generally were in the range of 1-100 pg/mL, whereas a recent report detected 100-fold higher INSL5 levels in human serum. 9 Importantly, however, with commercial immunoassays we were unable to detect INSL5 either in supernatants or lysates of primary colonic epithelial cultures that we routinely use to investigate secretion of GLP-1 and PYY from L-cells. As we were able to detect INSL5 in these cultures by immunohistochemistry, 3 we aimed to develop an independent assay suitable for the investigation of stimulus secretion coupling in these in vitro systems.
Over the last two decades, mass spectrometry (in combination with electrospray ionization) has become a powerful tool in the analysis of peptides, both for quantitative analysis and for identification of potential new functional peptides. Studies have included the analysis of primary islet cell cultures where significant numbers of glucagon gene products were identified. 10 More targeted mass spectrometry techniques using triple quadrupole systems have been employed to monitor peptides such as GLP-1 7-36 and 9-36 in established colorectal cell lines. 11 Furthermore, mass spectrometric approaches have proven to be sensitive enough to detect some gut hormone peptides at physiological (usually low pM or pg/mL) levels in circulating plasma. 12, 13 Mass spectrometry has also been successfully applied to the detection and quantitation of peptides from the insulin/relaxin family. In contrast to most immunoassays, mass spectrometry can readily distinguish between peptides with only subtle differences as for example endogenous human insulin and the closely related Humalog, which is isobaric and differs only by a transposition of the proline and lysine residues at the C-terminal end of the A-chain. 14 This study also demonstrated that mass spectrometric approaches can reach lower limits of quantitation in the region of 50 pg/mL in plasma for most of the insulin analogues. We thus investigated the possibility of using a MS-based assay for INSL5 that would also allow the characterisation of the exact peptide sequence of stored and secreted products derived from the prepropeptide.
2 | EXPERIMENTAL
| Materials
All reagents were purchased from Sigma Aldrich (Poole, UK), except acetonitrile, methanol and trypsin that were purchased from Fisher Scientific (Loughborough, UK), Matrigel and Draq5 that were purchased from BD Bioscience (Oxford, UK) and Y27632 from Tocris Bioscience (Bristol, UK). Murine INSL5 peptide was purchased from Phoenix Pharmaceuticals (Burlingame, CA, USA).
| Peptide extraction from FACS-sorted murine L-cells
Single cell suspensions of colonic epithelial cells were prepared with slight modifications to a previously described procedure. 15 detached from the tissue were centrifuged (300 g, 5min) after each step.
Pooled sediments were digested into single cells in 0.25% trypsin-EDTA for 5-10 min at 37°C. Single cells were washed and kept in cold HBSS with 0.1% BSA, Y27632 (10 μM), DAPI (1 μg/mL) and Draq5 (5 μM).
Single live L-cells were isolated based on forward and side scatter and Venus, DAPI and Draq5 fluorescence within 4 h using a FACSJazz (BD Biosciences, Singapore) at the Cambridge NIHR BRC Cell Phenotyping
Hub. Peptides were extracted using a method adapted from a validated approach for enriching peptides from plasma, [17] [18] [19] where a total of 6000-8000 positive cells were sorted and lysed directly into 800 μL of 80% ACN in water (v/v) in a Protein Lobind Eppendorf tube. Samples were centrifuged for 5 min at 10,000 g to pellet the proteins and the supernatant was transferred to a fresh tube and evaporated to dryness in an Eppendorf 5301 vacuum concentrator. Reduction and alkylation of disulphide bonds was performed (as described below) prior to LC/ MS analysis, and 10 μL was injected onto the system.
| Reduction and alkylation
The sorted cell peptide residue was reconstituted into 25 μL of 50 mM ammonium bicarbonate containing 10 mM DTT and heated at 60°C for 60 min. Then 5 μL of 100 mM iodoacetamide (IAA) in 50 mM ammonium bicarbonate were mixed in and the samples were stored in the dark for 30 min at room temperature and subsequently exposed to light for at least 30 min. 5 μL of 1% formic acid in water (v/v) was added prior to injection onto the LC/MS system.
| Tissue homogenisation
Mice (3-6 months old) were sacrificed by cervical dislocation and the colon was excised. For human colon, fresh surgical specimens were 
| Endogenous peptide identification
The acquired LC/MS files were searched using Peaks 8.0 software until extraction. Samples were extracted using the SPE method described above, and were analysed without reduction and alkylation to assess the intact form of INSL5.
| High flow rate analysis of primary colonic culture supernatants
A full scan analysis was performed on the extract using a high flow rate based LC/MS approach using a flow rate of 300 μL/min on the same instrumentation as described above. Solvents used for the separation 
| Precision and accuracy of the SPE approach
An attempt was made to develop a quantitative methodology for the intact murine INSL5 peptide using a commercially sourced murine INSL5 peptide. However, the characterisation of the peptide demonstrated it was different from the endogenous peptide, and therefore could not be used to generate a fully quantitative methodology.
The peptide was however used to assess the sensitivity, precision and accuracy of the SPE approach for a very closely related peptide to the endogenous protein. A calibration line of Phoenix INSL5
protein was generated in 0.001% BSA in 0.1% formic acid (v/v) over a range of 0.1-10 ng/mL. Seven calibration standards were generated (0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10 ng/mL); 0.5 mL of each standard was extracted via the SPE method described above, and 40 μL of sample was injected onto the LC/MS system. Four levels of QC were generated (0.1, 0.3, 1 and 8 ng/mL) and extracted six times in order to assess the precision and accuracy of the analysis. The calibration line followed a quadratic fit, as no internal standard was available to be able to correct for ionisation or adsorptive losses during the extraction process. Recovery of the peptide from the BSA solution was assessed by analysing a spiked solution before and after extraction at a concentration of 8 ng/mL. Figure 3D ) differing subtly from the predicted form indicated in the Swissprot database ( Figure 1A) and the synthesised form commercially available from Phoenix ( Figure 1B ). Our data corroborates the sequence of endogenous human INSL5 that is present in the Swissprot database ( Figure 1C ).
Mass spectrometric techniques have been applied to human INSL5
protein previously to characterise the prohormone cleavage sites after heterologous expression in a mammalian cell line (Cos7 co-overexpressing furin), identifying an identical mature form to the one reported here. 5 Whilst MS has been used to verify the sequence of recombinant and synthetically synthesised INSL5 variants, 22 to our knowledge, no endogenously expressed INSL5 has previously been analysed using LC/MS.
| LC/MS analysis of intact endogenous and synthetic INSL5 peptides
As INSL5 is supposed to be secreted from the colon, we assessed if we could detect the peptide in the supernatant of human and murine colonic primary cultures. Initially, we detected murine INSL5 in culture supernatants after reduction/alkylation, the A and B chain species resembling the ones observed in whole tissue lysates. Both human and mouse INSL5 could, however, also be detected intact, as can be seen in the insets of Figures 3A and 3C . The inset of Figure 3A shows three-dimensional structure. However, the addition of the serine residue means that mass spectrometric analysis approaches are compromised due to the significant change in the mass of the peptide.
One potential approach to use the Phoenix peptide for quantitative studies is to reduce and alkylate the peptide, separating the two chains and analysing the A chain only, as this is identical to the endogenous version. However, using this approach would result in the loss of structural information, where any cleavages or modifications to the B chain would be lost if only the A chain is monitored.
| Assessment of the precision and accuracy of the SPE method
The precision and accuracy of the SPE-based LC/MS method was assessed over a concentration range of 0.1-10 ng/mL using the The focus of the method development then shifted from identification to quantitation on secreted intact INSL5. An SPE-based methodology was developed that was capable of extracting INSL5
from the supernatant and concentrating it significantly, such that the intact peptide could be detected and quantified using a high flow rate analysis approach. Whilst a high flow rate analysis is less sensitive than in plasma, as we expect these to be in the pM (pg/mL) range, similar the intestinal hormones GLP-1 and PYY, which are co-secreted from L-cells. It is likely that in order to detect endogenous INSL5 in plasma, large plasma sample volumes could be required (not feasible in rodent models); however, nano-LC/MS/MS and targeted SRM detection could achieve the required sensitivity with limited volume samples. Furthermore, the investigation of a hybrid immuno-affinity LC/MS/MS analysis approach might be required, which was successfully employed to quantify circulating proglucagon products in human plasma. 13 However, here we demonstrated an approach to measure secreted and cellular INSL5 levels in mouse and human samples that should enable further research investigating the production and secretion of this peptide recently implicated to play a role in metabolic homeostasis.
